Siamab’s ST1 Therapy Candidate Promising Against Chemoresistant Ovarian Cancer, Study Shows

Siamab’s ST1 Therapy Candidate Promising Against Chemoresistant Ovarian Cancer, Study Shows
Siamab Therapeutics‘ investigational antibody-drug conjugate ST1 has promising anti-tumor effects against chemotherapy-resistant ovarian cancer in cell and animal models, a study shows.  The study, “Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau,” was published in the journal Oncotarget. Tumor chemoresistance and recurrence is a serious health-threatening issue, affecting most women with ovarian cancer. New treatment

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *